NASDAQ:BIAF bioAffinity Technologies (BIAF) Stock Price, News & Analysis $2.71 +0.03 (+1.12%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.66▼$2.8150-Day Range$1.76▼$2.8252-Week Range$0.95▼$3.62Volume115,371 shsAverage Volume143,944 shsMarket Capitalization$31.60 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get bioAffinity Technologies alerts: Email Address bioAffinity Technologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside121.4% Upside$6.00 Price TargetShort InterestBearish10.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.48 out of 5 starsMedical Sector735th out of 936 stocksCommercial Physical Research Industry11th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingbioAffinity Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragebioAffinity Technologies has only been the subject of 1 research reports in the past 90 days.Read more about bioAffinity Technologies' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.72% of the float of bioAffinity Technologies has been sold short.Short Interest Ratio / Days to CoverbioAffinity Technologies has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in bioAffinity Technologies has recently increased by 9.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldbioAffinity Technologies does not currently pay a dividend.Dividend GrowthbioAffinity Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIAF. Previous Next 3.0 News and Social Media Coverage News SentimentbioAffinity Technologies has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for bioAffinity Technologies this week, compared to 0 articles on an average week.Search Interest2 people have searched for BIAF on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added bioAffinity Technologies to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.Percentage Held by Insiders36.44% of the stock of bioAffinity Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.64% of the stock of bioAffinity Technologies is held by institutions.Read more about bioAffinity Technologies' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of bioAffinity Technologies is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bioAffinity Technologies is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiobioAffinity Technologies has a P/B Ratio of 5.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about bioAffinity Technologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About bioAffinity Technologies Stock (NASDAQ:BIAF)bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.Read More BIAF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIAF Stock News HeadlinesJuly 24 at 7:50 PM | msn.comMaxim Group Initiates Coverage of bioAffinity Technologies (BIAF) with Buy RecommendationJuly 24 at 1:49 PM | americanbankingnews.combioAffinity Technologies (NASDAQ:BIAF) Coverage Initiated by Analysts at Maxim GroupJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."June 12, 2024 | businesswire.combioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung TestsMay 15, 2024 | msn.comBIAF Stock Earnings: bioAffinity Technologies Reported Results for Q1 2024May 15, 2024 | businesswire.combioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory VolumesMay 2, 2024 | businesswire.combioAffinity Technologies News UpdateApril 26, 2024 | investing.combioAffinity Technologies appoints VP to enhance diagnosticsJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."April 24, 2024 | businesswire.combioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of GrowthApril 9, 2024 | finance.yahoo.combioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer ScreeningApril 9, 2024 | businesswire.combioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer ScreeningMarch 8, 2024 | finance.yahoo.combioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private PlacementMarch 8, 2024 | finance.yahoo.comWallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private PlacementMarch 6, 2024 | msn.comNasdaq Gains 100 Points; Campbell Soup Earnings Top ViewsMarch 6, 2024 | marketwatch.comBioAffinity Technologies Shares Plummet After Stock SaleMarch 6, 2024 | msn.comWhy BioAffinity Technologies (BIAF) Shares Are Down 50%March 6, 2024 | msn.comBioAffinity Technologies to raise $2.5M from stock offering and private placementSee More Headlines Receive BIAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:BIAF CUSIPN/A CIK1712762 Webwww.bioaffinitytech.com Phone210-698-5334FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+121.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,940,000.00 Net Margins-171.43% Pretax Margin-169.16% Return on Equity-134.34% Return on Assets-95.83% Debt Debt-to-Equity Ratio0.14 Current Ratio2.22 Quick Ratio2.21 Sales & Book Value Annual Sales$2.53 million Price / Sales12.49 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book5.31Miscellaneous Outstanding Shares11,660,000Free Float7,410,000Market Cap$31.60 million OptionableNot Optionable Beta2.99 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Steven Girgenti (Age 78)Founder & Executive Chairman of the Board Comp: $113.75kMs. Maria Zannes J.D. (Age 68)Founder, President, CEO & Director Comp: $299.17kMs. Julie Anne OvertonDirector of CommunicationsMr. Dallas J. ColemanNational Director of SalesDr. William Bauta Ph.D.Senior Vice President of TherapeuticsKey CompetitorsVeritoneNASDAQ:VERIMastech DigitalNYSE:MHHSo-Young InternationalNASDAQ:SYVacasaNASDAQ:VCSALuna InnovationsNASDAQ:LUNAView All Competitors BIAF Stock Analysis - Frequently Asked Questions How have BIAF shares performed this year? bioAffinity Technologies' stock was trading at $1.4705 at the beginning of the year. Since then, BIAF shares have increased by 84.3% and is now trading at $2.71. View the best growth stocks for 2024 here. How were bioAffinity Technologies' earnings last quarter? bioAffinity Technologies, Inc. (NASDAQ:BIAF) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.21) earnings per share for the quarter. The business had revenue of $2.41 million for the quarter. bioAffinity Technologies had a negative net margin of 171.43% and a negative trailing twelve-month return on equity of 134.34%. When did bioAffinity Technologies IPO? bioAffinity Technologies (BIAF) raised $8 million in an IPO on Thursday, September 1st 2022. The company issued 1,300,000 shares at a price of $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager. How do I buy shares of bioAffinity Technologies? Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIAF) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bioAffinity Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
